Antihistamines News and Research

RSS

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

Lanzoprazole and astemizole hold promise for early detection of AD

Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease. The study is published in the current issue of the Journal of Alzheimer's Disease.

30 Jan 2010

Over-the-counter medications can help manage minor ailments

Nonprescription medications in the home medicine cabinet could save a trip to the doctor. The January issue of Mayo Clinic Health Letter lists more than a dozen over-the-counter medications that can help manage minor ailments.

18 Jan 2010

Inadequate saliva and fluoride can contribute to tooth decay

Tooth enamel is tough, harder even than skeletal bone. But even with good dental hygiene, the enamel protecting teeth may show signs of decay in older adults. The January issue of Mayo Clinic Health Letter covers what to look out for and what to do to promote an enamel-friendly setting in the mouth. According to the newsletter, two significant contributors to tooth decay are too little saliva and inadequate fluoride.

18 Jan 2010

Johns Hopkins scientists find a source of nonallergic itch

Scratching below the surface of a troublesome sensation that's equal parts tingle-tickle-prickle, sensory scientists from Johns Hopkins have discovered in mice a molecular basis for nonallergic itch.

23 Dec 2009

Sanofi-aventis to acquire Chattem for $1.9 billion

Sanofi-aventis and Chattem, Inc. announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion.

21 Dec 2009

Stallergenes granted European approval to market Oralair

Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.

27 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

AMRI reports $47.7 million total revenue for the third quarter of 2009

AMRI today reported financial and operating results for the third quarter ended September 30, 2009.

9 Nov 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Azelastine and fluticasone combination for allergic rhinitis gets new lease

Meda and Cipla Ltd, a leading pharma company in India, have expanded the existing long term collaboration agreement for the combination of azelastine and fluticasone.

8 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

FDA approves Astepro nasal spray 0.15% for the treatment of the symptoms of seasonal allergies

The U.S. Food and Drug Administration (FDA) has approved Astepro (azelastine) nasal spray 0.15% for the treatment of the symptoms of seasonal and perennial allergic rhinitis.

2 Sep 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

10 Aug 2009

American Oriental Bioengineering launches new product for rhinitis and allergies

American Oriental Bioengineering, Inc. today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.

7 Aug 2009